'Lifeline' neonatal service in the North East is saved by new funding
A neonatal unit hailed as a 'lifeline' in the North East has been saved by new vital funding after facing an uncertain future due to financial difficulties.
Leo's Neonatal, the only dedicated neonatal trauma support service in the region, has received backing from law firm Slater and Gordon.
The Teesside-based charity, which supports the mental health and wellbeing of families affected by neonatal trauma, had been at risk of reducing its services due to a drop in funding and donations.
(Image: LEO'S NEONATAL CHARITY) Founded in 2018, Leo's provides therapies such as Eye Movement Desensitisation and Reprocessing (EMDR), trauma-focused talking therapies, Flash and Cognitive Behavioural Therapy (CBT).
The charity has thousands of contacts with families across the North East each year and has seen increasing demand, with a 100 percent referral rate for mental health support from clinical staff.
However, due to a drop in funding and donations, Leo's was forced to consider the future of some of its services – including its neonatal trauma support, which is the only dedicated service of its kind in the region, offering specialist lived experience mentoring and targeted trauma interventions.
(Image: LEO'S NEONATAL CHARITY) Leo's founder and CEO, Lottie King, said losing the trauma support service would have been devastating for parents facing grief and trauma.
Lottie established the charity in memory of her son, Leo, who died shortly after birth in 2015. His twin, Oska, was in the Special Care Baby Unit at North Tees Hospital for over 100 days after being born four days later.
Now, law firm Slater and Gordon has partnered with Leo's – which received a Points of Light award from then-Prime Minister Boris Johnson for its life-changing impact – to deliver the funding to enable its specialist support for families in need to continue.
Lottie said: 'Our neonatal trauma service has proved a lifeline to so many parents and it would have been absolutely devastating if we had to close.
'The need for specialist support for neonatal parents who have been impacted by grief and trauma is massive and increasing all the time, and it doesn't bear thinking about if we had to turn them away.
"In addition to the huge pressure on NHS resources and long waiting lists for mental health support, there is no guarantee parents affected by neonatal trauma will be able to see a specialist – and at Leo's, our team know through their own lived experience how vital it is that specialist support is available."
READ MORE:
Fight for charity helping sick babies in North East
UK's first Neonatal Mental Health Awareness Week launched by Leo's
Baby's hearts to beat on forever with Leo's 'heartbeat bears'
John Lowther, senior associate at Slater and Gordon in Newcastle, said: 'Leo's Neonatal has supported countless families across our region during some of their darkest days, and demand for their services is growing all the time.
"This charity was born out of lived experience and has identified a range of areas in which specialist therapies, support and interventions can positively impact the lives of parents and children at times when they need it most.
'We are really delighted to partner with Lottie and her amazing team, and to be able to give our backing to the dedicated neonatal trauma support service, which we know plays such a critical role in the mental health of so many parents.
"Knowing the impact of this service, and the growing demand Leo's faces to deliver it, its closure is unthinkable. We are so pleased we can help them to continue their life-changing work.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
5 hours ago
- Business Insider
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:


Business Insider
5 hours ago
- Business Insider
Guardant Health presented results of largest study on ctDNA in colon cancer
Guardant Health (GH) presented results of the largest study to date evaluating circulating tumor DNA, ctDNA, in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment.
Yahoo
7 hours ago
- Yahoo
Two people rescued from small plane crash in Long Island Sound
June 1 (UPI) -- Crews rescued two people aboard a small plane that crashed into Long Island Sound Sunday near a Connecticut airport, according to the FAA and U.S. Coast Guard. The Piper PA-32 plane went down about 10:30 a.m. south of the Tweed New Haven Airport in New Haven, a statement from the FAA said. "The two persons onboard the aircraft were rescued and in stable condition," the Coast Guard said in a statement, according to ABC News. The Coast Guard dispatched a 45-foot New Haven-based rescue boat to the scene after the Sector Long Island Sound Command Center received notification of the incident from the air traffic control tower that the plane had gone down near the Thimble Islands close to Branford, Ct. The rescued passengers were taken to the Stony Creek Pier in Branford, the Coast Guard said. The FAA is investigating the incident.